|
||||||
|
|
|
|
|
||
iSBTc NewsPress ReleaseFor Immediate Release For more information, contact: DEBATE OVER DENDREON'S PROVENGE DISCUSSED AT ISBTC ANNUAL MEETING BOSTON---The International Society for Biological Therapy of Cancer (iSBTc) hosted an educational session entitled the "The Dendreon Debate," during the recent 22nd Annual Meeting Program in Boston, MA. This session focused on the recent developments surrounding Provenge, Dendreon's prostate cancer vaccine, and included presentations and a panel discussion concerning lessons learned from the recent review of the Provenge program by the US Food & Drug Administration as well as the ensuing events subsequent to this review. Provenge has been designed to stimulate a patient's own immune system to destroy prostate cancer. "This iSBTc forum provided membership with an open and balanced discussion by expert panelists that included a past Division Director from FDA, the CSO of Dendreon, their consulting statistician as well as physician scientists who are world experts in DCs and immunotherapy trials," stated iSBTc Vice President, Bernard Fox, PhD. "This open discussion resulted in general agreement of the FDA's recent decision to await the results of Phase III studies." The session was moderated by iSBTc Vice President and President, Bernard A. Fox, PhD (Earle A. Chiles Research Institute) and Jon M. Wigginton, MD (Merck & Co., Inc.). Panelists included leaders in the field of cancer research, trial design and patient treatment includingy including Brent A. Blumenstein, PhD (TriArc Consultin), Lee S. Simon, MD (Beth Israel Deaconess Medical Center), David L. Urdal, PhD (Dendreon Corporation), Charles Drake, MD, PhD (Johns Hopkins University School of Medicine), and James W. Young, MD (Memorial Sloan-Kettering Cancer Center). Founded in 1984, the International Society for Biological Therapy of Cancer (iSBTc) is a non profit organization of clinicians, researchers, students, post-doctoral fellows, and allied health professionals dedicated to improving cancer patient outcomes by advancing the development and application of biological therapy through interaction, innovation and leadership. ###
|
|
|